February 27, 2020 | Vensana in the News

Vensana—Is Medtech Investing on the Rebound?

21

Novel FDA PMA & de novo 510k approvals

60

U.S. Commercial Product Launches

39

Level I Clinical Trials

31

Strategic Financings

31

Exits by IPO or M&A